Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ABEO Abeona Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ABEO
Price (delayed)
$5.89
Market cap
$301.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.82
Enterprise value
$309.02M
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis
Highlights
ABEO's EPS has soared by 74% year-on-year and by 47% since the previous quarter
Abeona Therapeutics's net income has increased by 42% YoY and by 31% QoQ
The revenue has dropped by 100% year-on-year
The company's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of ABEO
Market
Valuations
Earnings
Shares outstanding
51.16M
Market cap
$301.31M
Enterprise value
$309.02M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.91
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$69.61M
Net income
-$44.19M
EBIT
-$39.93M
EBITDA
-$36.93M
Free cash flow
-$62.98M
Per share
Balance sheet
Liquidity
EPS
-$0.82
EPS diluted
-$1.27
Free cash flow per share
-$1.27
Book value per share
$0.85
Revenue per share
$0
TBVPS
$2
Total assets
$99.36M
Total liabilities
$57.97M
Debt
$23.98M
Equity
$41.4M
Working capital
$70.14M
Debt to equity
0.58
Current ratio
4.9
Quick ratio
4.79
Net debt/EBITDA
-0.21
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-38.2%
Return on equity
-86.5%
Return on invested capital
-40.4%
Return on capital employed
-49.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABEO stock price
How has the Abeona Therapeutics stock price performed over time
Intraday
-1.83%
1 week
-4.38%
1 month
-8.26%
1 year
30.31%
YTD
5.75%
QTD
23.74%
Financial performance
How have Abeona Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$69.61M
Net income
-$44.19M
Gross margin
N/A
Net margin
N/A
The revenue has dropped by 100% year-on-year
The company's gross profit has shrunk by 100% YoY
The operating income has decreased by 46% YoY and by 8% from the previous quarter
Abeona Therapeutics's net income has increased by 42% YoY and by 31% QoQ
Price vs fundamentals
How does ABEO's price correlate with its fundamentals
Growth
What is Abeona Therapeutics's growth rate over time
Valuation
What is Abeona Therapeutics stock price valuation
P/E
N/A
P/B
6.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ABEO's EPS has soared by 74% year-on-year and by 47% since the previous quarter
The price to book (P/B) is 123% higher than the 5-year quarterly average of 3.1 and 41% higher than the last 4 quarters average of 4.9
Abeona Therapeutics's equity has decreased by 6% QoQ
The revenue has dropped by 100% year-on-year
Efficiency
How efficient is Abeona Therapeutics business performance
Abeona Therapeutics's return on equity has surged by 89% YoY and by 48% QoQ
The company's return on invested capital has surged by 72% YoY and by 36% QoQ
The company's return on assets has surged by 68% YoY and by 34% QoQ
Dividends
What is ABEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABEO.
Financial health
How did Abeona Therapeutics financials performed over time
The company's total assets is 71% higher than its total liabilities
The company's total assets rose by 33% YoY but it fell by 9% QoQ
ABEO's total liabilities is down by 31% YoY and by 11% QoQ
Abeona Therapeutics's debt is 42% lower than its equity
Abeona Therapeutics's debt to equity has surged by 122% YoY and by 12% QoQ
Abeona Therapeutics's equity has decreased by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.